Histopathological subtyping is a prognostic factor in stage IV lung adenocarcinoma.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
09 2020
Historique:
received: 11 05 2020
revised: 30 06 2020
accepted: 06 07 2020
pubmed: 19 7 2020
medline: 22 6 2021
entrez: 19 7 2020
Statut: ppublish

Résumé

Lung adenocarcinoma is a heterogeneous tumor made of different architectural patterns. These tumors are classified into subtypes according to the predominant pattern in the primary tumor because the predominant pattern is related to overall survival. The prognostic role of these subtypes in stage IV disease is not well known, and most lung adenocarcinomas are diagnosed at the stage of metastatic disease. We aimed to evaluate the prognostic role of histopathological subtypes in lung adenocarcinoma metastases in a retrospective study of 253 patients with clinical, histopathological and molecular data. The presence of the solid subtype was related to overall survival (p = 0.045); the median overall survival was 6.8 months (95 % confidence interval (95 %CI) 4.4-9.1) when present and 11.1 months (95 %CI 8.6-21.3) when absent. Thyroid transcription factor 1 (TTF-1) immunohistochemistry was related to overall survival (p < 0.001); the median overall survival was 11.2 months (95 %CI 8.4-17.7) when positive and 4 months (95 %CI 2.3-5.7) when negative. On multivariate analysis, the presence of the solid subtype (p = 0.0036, hazard ratio (HR) 1.55, 95 %CI 1.03-2.34), TTF-1 positivity (p = 0.044, HR 0.64, 95 %CI 0.42-0.98), age <60 years at the time of resection (p = 0.017, HR 1.89; 95 %CI 1.12-3.21), performance status <2 (p = 0.017, HR 0.57; 95 %CI 0.36-0.91), treatment by chemotherapy (p = 0.033, HR 0.54, 95 %CI 0.31-0.95), and treatment by tyrosine kinase inhibitor or immunotherapy (p = 0.013, HR 0.36, 95 %CI 0.17-0.81) were related to overall survival. The evaluation of architectural pattern in metastases in stage IV patients provides further information for physicians about patient prognosis. This information might be included in clinical trials in patients with stage IV lung adenocarcinoma.

Identifiants

pubmed: 32682188
pii: S0169-5002(20)30521-3
doi: 10.1016/j.lungcan.2020.07.010
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

77-82

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Vanessa Da Cruz (V)

Department of Pathology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Violaine Yvorel (V)

Department of Pathology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

François Casteillo (F)

Department of Pathology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Claire Tissot (C)

Department of Pneumology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Antoine Luchez (A)

Department of Pneumology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Sophie Bayle-Bleuez (S)

Department of Pneumology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Pierre Fournel (P)

Department of Medical Oncology Lucien Neuwirth Cancer Institute 42270 Saint Priest-En-Jarez, France.

Olivier Tiffet (O)

Department of Thoracic Surgery, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Michel Péoc'h (M)

Department of Pathology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France.

Fabien Forest (F)

Department of Pathology, University Hospital of Saint Etienne, North Hospital, Avenue Albert Raimond, 42055 Saint Etienne CEDEX 2, France; Corneal Graft Biology, Engineering and Imaging Laboratory, BiiGC, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, EA2521, France. Electronic address: f.forest@univ-st-etienne.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH